Sinotherapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese pharma company developing complex generics and novel formulations with FDA/NMPA-approved products in oncology, immunology, and metabolic diseases.
OncologyImmunologyGastroenterologyMetabolismNeurologyCardiologyNephrology
Technology Platform
Four specialized R&D platforms: enhanced solubilization of poorly-water-soluble compounds, sustained/controlled release drug products, fixed-dose combination products, and topical drug products.
Opportunities
Expansion into Southeast Asian markets through partnership with Kalbe Farma, and growing global demand for complex generics and 505(b)(2) products in multiple therapeutic areas.
Risk Factors
Generic pharmaceutical pricing pressure, potential patent litigation from originator companies, and increasing regulatory complexity for approval of complex generic products.
Competitive Landscape
Competes with other complex generic manufacturers like Teva, Mylan, and Sun Pharma, but differentiates through specialized formulation platforms for poorly-soluble drugs and dual FDA/NMPA approval capability.